On 12 February 2025, around 30 delegates from 20 member companies visited the Greater Bay International Clinical Trial Institute (GBAICTI) and Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone (HTCZ).

The GBAICTI is poised to become a pivotal hub for clinical trial network cooperation between Hong Kong and the Mainland, serving as a platform to support medical research institutions both within and outside of Hong Kong, coordinating the launch of multi-centre cross-boundary clinical trials.

This visit underscores HKAPI’s commitment to fostering collaboration with key stakeholders and enhancing clinical research capabilities of Hong Kong.